Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

Essential thrombocythemia (ET) is a BCR-ABL1-negative myeloproliferative neoplasm, the most common clinical manifestations of which include arterial and venous thrombosis, bleeding and vasomotor/microvascular disturbances. Low-dose (81-100 mg) aspirin once daily, which irreversibly inhibits platelet...

Descripción completa

Detalles Bibliográficos
Autor principal: Cattaneo, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230439/
https://www.ncbi.nlm.nih.gov/pubmed/36632735
http://dx.doi.org/10.3324/haematol.2022.281388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230439/
https://www.ncbi.nlm.nih.gov/pubmed/36632735
http://dx.doi.org/10.3324/haematol.2022.281388

Ejemplares similares